Free Trial

BriaCell Therapeutics 6/14/2024 Earnings Report

BriaCell Therapeutics logo
$0.39 +0.02 (+4.23%)
As of 01/21/2025 04:00 PM Eastern

BriaCell Therapeutics EPS Results

Actual EPS
$0.11
Consensus EPS
-$0.55
Beat/Miss
Beat by +$0.66
One Year Ago EPS
N/A

BriaCell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BriaCell Therapeutics Announcement Details

Quarter
Time
After Market Closes

Conference Call Resources

BriaCell Therapeutics Earnings Headlines

The #1 Stock for Trump’s Second Term?
Imagine how much money you could make if you bought all of the top performing stocks during Trump's second term? Well, legendary investor Louis Navellier's stock rating system... Gave a buy rating to ALL of the top 30 performing stocks in the S&P 500 index of Trump's first term...
See More BriaCell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BriaCell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BriaCell Therapeutics and other key companies, straight to your email.

About BriaCell Therapeutics

BriaCell Therapeutics (NASDAQ:BCTX), a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View BriaCell Therapeutics Profile

More Earnings Resources from MarketBeat